ClinicalTrials.gg
CompletedNCT06881836Updated Oct 22, 2026

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

A Phase 2 interventional study of ONO-2020 and Placebo in Alzheimer Disease, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 80 sites in 2 countries. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 22, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
351st of 1,609
260 · median 73
Started
2025
with 98 others
Phase 2
360 of 1,940
50 open now
Registered
1,794th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 351st largest by enrollment of the 1,609 interventional ones that give a count, is one of 99 that started in 2025, is one of 360 in phase 2, and was the 1,794th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

Read the detailed description

In the study, participants will undergo a screening period of up to 6 weeks (42 days). Eligible participants will be assigned to receive one of 2 dose levels of ONO-2020 or placebo control arm. ONO-2020 or placebo will be administered orally QD for 26 weeks. All participants who received study intervention will be followed up for 4 weeks after treatment discontinuation. The target sample size is 240 participants , out of which up to 45 participants will undergo additional special CSF biomarker evaluation. After enrollment, participants will be randomized in a 1:1:1 ratio to one of 3 treatment arms.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Alzheimer Disease
  • mild to moderate Alzheimer Disease
  • Dementia
  • ONO-2020
  • mild Alzheimer Disease
  • moderate Alzheimer Disease
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a diagnosis of Alzheimer's disease according to the recommendations from the revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup , along with any positive AD-specific biomarker results (abnormal Core 1 or Core 2 biomarkers) from a previous diagnosis or at screening.
  2. Have a previous MRI or CT scan of the brain, which was performed within 1 year prior to enrollment in the study, to confirm that more recent neurological events (e.g., stroke) would not potentially constitute a confounder in the assessment of the etiology of the participant's cognitive status.
  3. score of 15 to 24, inclusive, and MMSE score cannot deviate more than 3 points in either direction between the screening and baseline visits.
  4. AD numeric clinical stage 4 or stage 5 based on NIA-AA criteria 2024, at screening and baseline visits
  5. Participants receiving concurrent AD treatment (acetylcholinesterase inhibitors and /or memantine) must be on a stable dose for at least 90 days prior to randomization, and the participant must be willing to remain on the same dose for the duration of the study.
  6. Have the ability to comply with procedures for cognitive and other tests in the opinion of the investigator
  7. If female, for at least 1 year
  8. Non-vasectomized male participants with female partners of must agree to use an effective method of from dosing on Day 1 until 3 months after the last administration of study intervention and agree not to donate sperm until 3 months after the last administration of study intervention.
  9. Participant must have a Caregiver who has frequent contact with the participant (defined as at least 8 hours per week spread across 3\~4 visits per week) to provide support to the participant to ensure compliance with study requirements. The Caregiver must be willing to consent to participate in this study, to provide a rating of the extent and severity of change of the participant's memory, problem-solving abilities, or activities of daily living from prior abilities.
  10. General health status acceptable for participation in the study, and the participant must be able to ingest pills.
  11. Participant and his/her Caregiver have provided full written prior to the performance of any protocol-specified procedure; or if a participant is unable to provide informed consent due to cognitive status, he/she has provided assent, and a legally acceptable representative (LAR) has provided full written informed consent on behalf of the participant.

Exclusion criteria

Exclusion Criteria:

  1. Participants with dementia or other memory impairment not due to Alzheimer's disease, including, but not limited to, dementia with Lewy bodies, vascular dementia, Parkinson's disease, Huntington disease, corticobasal degeneration, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal degeneration, normal pressure hydrocephalus, hypoxia, severe sleep apnea or other chronic sleep disturbance, or baseline intellectual disability.
  2. Participants with a history of stroke, well-documented , or pulmonary or cerebral embolism.
  3. History of significant psychiatric illness such as schizophrenia or bipolar affective disorder, or history or current major depressive disorder in the past year and any other significant psychiatric illness that in the opinion of the investigator could interfere with participation in the study.
  4. Participants with delirium or history of delirium within the 30 days prior to the screening visit.
  5. Have suicide ideation according to the investigator's clinical judgment as per the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening or have made a suicide attempt in the 6 months prior to screening.
  6. abnormality as judged by the investigator.
  7. Confirmed absolute >450 msec for males or >470 msec for females.
  8. Positive results at screening for active viral infections that include (HIV), surface antigen (HBsAg), and virus (HCV) RNA PCR test.
  9. Participants with total , (ALT) or aspartate transaminase (AST) greater than 1.5× (ULN), or (INR) greater than 1.7 at screening.
  10. Participants with estimated (CrCL, Cockcroft-Gault equation) ≤30 mL/min at screening.
  11. Participants with a history of treatment, and/or current treatment, with anti-Aβ antibodies
  12. Changes in any medications that, in the opinion of the investigator, may potentially impair participants' ability to perform cognitive testing or study procedures during the study period (from Screening to EOT), and their dosing should be stable for at least 1 month before Screening (such as benzodiazepines and sedatives/hypnotics). All concomitant medications must be kept as stable as medically possible during the study.
  13. Participants who have taken any products, or used investigational medical devices, within 3 months or five half-lives of the therapy (whichever is longer) with respect to first dosing and throughout the study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    ONO-2020 Dose 1

    Participants will receive ONO-2020 Dose 1 administered orally, once a day (QD) for 26 weeks.

    Drug: ONO-2020

  • Experimental
    ONO-2020 Dose 2

    Participants will receive ONO-2020 Dose 2 administered orally, once a day (QD) for 26 weeks.

    Drug: ONO-2020

  • Placebo comparator
    Placebo

    Participants will receive Placebo administered orally, once a day (QD) for 26 weeks.

    Drug: Placebo

Interventions

  • ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily.

  • DrugPlacebo

    Placebo group: Two ONO-2020 placebo tablets will be orally administered once daily.

06

What researchers measure

Primary outcomes

  1. Incidence, severity, and type of treatment emergent adverse events (TEAEs)

    The number and percentage of subjects reporting each TEAE will be summarized by both system organ class (SOC) and preferred term (PT).

    Time frame: From baseline up to 26 weeks

  2. Clinically abnormal findings in Columbia Suicide Severity Rating Scale (C-SSRS)

    The number and percentage of subjects with clinically abnormal finding will be tabulated at each time point.

    Time frame: From baseline up to 26 weeks

  3. Change from baseline through week 26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 12 (ADAS-cog 12) score

    Time frame: From baseline up to 26 weeks

Secondary outcomes

  1. Change from baseline through week 26 in ADAS-cog 12 score in mild AD participants

    Time frame: From baseline up to 26 weeks

  2. Change from baseline through week 26 in ADAS-cog 12 score in moderate AD participants

    Time frame: From baseline up to 26 weeks

  3. Change from baseline through week 26 in ADAS-cog 11 and 13 scores

    Time frame: From baseline up to 26 weeks

  4. Change from baseline through week 26 in Alzheimer's Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL) score

    Time frame: From baseline up to 26 weeks

  5. Change from baseline through week 26 in Quick Dementia Rating System (QDRS)

    Time frame: From baseline up to 26 weeks

  6. Change from baseline through week 26 in Mini-Mental State Examination (MMSE) score

    Time frame: From baseline up to 26 weeks

  7. Change from baseline through week 26 in Neuropsychiatric Inventory Questionnaire (NPI-Q)

    Time frame: From baseline up to 26 weeks

  8. Change from baseline through week 26 in Quality of Life-Alzheimer's Disease (QoL-AD) Scale

    Time frame: From baseline up to 26 weeks

  9. Change from baseline through week 26 in Zarit Burden Interview Scale (ZBI)

    Time frame: From baseline up to 26 weeks

  10. Change in plasma concentration of ONO-2020 by dose level and time point

    The plasma concentrations of ONO-2020 will be listed, and descriptive summary statistics of them will be calculated by dose level and time point.

    Time frame: Day 1, Week 2, Week 10, and Week 26

07

Study locations

80 sites
  • Banner Alzheimer's Institute (BAI)
    Phoenix, Arizona 85006, United States
  • Clinical Endpoints
    Scottsdale, Arizona 85258, United States
  • Banner Sun Health Research Institute
    Sun City, Arizona 85351, United States
  • Center for Neurosciences-Research
    Tucson, Arizona 85718, United States
  • Profound Research LLC at The Neurology Center of Southern California
    Carlsbad, California 92011, United States
  • Neurology Center of North Orange County
    Fullerton, California 92835, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Sunwise Clinical Research
    Walnut Creek, California 94596, United States
  • CenExel Rocky Mountain Clinical Research
    Englewood, Colorado 80113, United States
  • Brain Matters Research
    Delray Beach, Florida 33445, United States
  • Quantum Clinical Trials
    Miami Beach, Florida 33140, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Charter Research - Orlando
    Orlando, Florida 32803, United States
  • Accel Research Sites - Brain and Spine Institute
    Port Orange, Florida 32127, United States
  • USF Health Byrd Alzheimer's Institute
    Tampa, Florida 33613, United States
  • ForCare Clinical Research
    Tampa, Florida 33647, United States
  • Charter Research - The Villages
    The Villages, Florida 32162, United States
  • Conquest Research LLC
    Winter Park, Florida 32789, United States
  • Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies CRU
    Decatur, Georgia 30030, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Velocity Clinical Research, Boise
    Meridian, Idaho 83642, United States
  • Re:Cognition Health-Chicago
    Chicago, Illinois 60611, United States
  • Ascension Alexian Brothers Medical Center
    Elk Grove Village, Illinois 60007, United States
  • University of Kansas Medical Center
    Fairway, Kansas 66205, United States
  • Univ of Kentucky Sanders-Brown Center on Aging
    Lexington, Kentucky 40504, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • ActivMed Research
    Methuen, Massachusetts 01844, United States
  • Cleveland Clinic Lou Ruvo Center for Brain Health
    Las Vegas, Nevada 89106, United States
  • Vector Clinical Trials
    Las Vegas, Nevada 89128, United States
  • The Cognitive and Research Center of New Jersey
    Springfield, New Jersey 07081, United States
  • Advanced Memory Research Institute of NJ (CenExel AMRI)
    Toms River, New Jersey 08755, United States
  • Advanced Clinical Institute Inc.
    West Long Branch, New Jersey 07764, United States
  • University at Buffalo
    Buffalo, New York 14203, United States
  • The Feinstein Institutes for Medical Research
    Manhasset, New York 11030, United States
  • NYU Center for Cognitive Neurology
    New York, New York 10016, United States
  • AD-CARE; University of Rochester
    Rochester, New York 14620, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
  • New Hope Clinical Research
    Charlotte, North Carolina 28211, United States
  • Velocity Clinical Research at Raleigh Neurology
    Raleigh, North Carolina 27607, United States
  • NeuroScience Research Center
    Canton, Ohio 44718, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University
    Columbus, Ohio 43221, United States
  • Neurology Diagnostics Research
    Dayton, Ohio 45459, United States
  • Neuro Behavioral Clinical Research, Inc.
    North Canton, Ohio 44720, United States
  • Neural Net Research / Center for Cognitive Health
    Portland, Oregon 97225, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Penn Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Neurology Clinic, P.C.
    Cordova, Tennessee 38018, United States
  • Vanderbilt UMC-Cognitive Med
    Nashville, Tennessee 37212, United States
  • Horizon Clinical Research Group
    Cypress, Texas 77429, United States
  • Texas Neurology
    Dallas, Texas 75206, United States
  • Olympus Clinical Research - Katy
    Katy, Texas 77450, United States
  • Be Well Clinical Studies
    Round Rock, Texas 78681, United States
  • Central Texas Neurology Consultants
    Round Rock, Texas 78681, United States
  • Grayline Research Center
    Wichita Falls, Texas 76309, United States
  • Re:Cognition Health - Fairfax
    Fairfax, Virginia 22031, United States
  • Kingfisher Cooperative; LLC
    Spokane, Washington 99201, United States
  • National Center for Geriatrics and Gerontology
    Aichi, Japan
  • Inage Neurology and Memory Clinic
    Chiba, Japan
  • Mabashi Clinic
    Chiba, Japan
  • Southern Tohoku Medical Clinic
    Fukushima, Japan
  • Ikuseikai Shinozuka Hospital
    Gunma, Japan
  • Imon Yukari Neurology Clinic
    Hiroshima, Japan
  • NHO Hiroshima-Nishi Medical Center
    Hiroshima, Japan
  • Himeji Central Hospital Clinic
    Hyōgo, Japan
  • Kobe City Medical Center General Hospital
    Hyōgo, Japan
  • Memory Clinic Toride
    Ibaraki, Japan
  • Kagawa Prefectural Central Hospital
    Kagawa, Japan
  • Meiwakai Izaki Clinic
    Nagasaki, Japan
  • Katayama Medical Clinic
    Okayama, Japan
  • Takesato Hospital
    Saitama, Japan
  • Jichiidai Station Brain Clinic
    Tochigi, Japan
  • Ichiekai Itsuki Hospital
    Tokushima, Japan
  • Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital
    Tokyo, Japan
  • Memory Clinic Ochanomizu
    Tokyo, Japan
  • Tokyo Medical University Hospital
    Tokyo, Japan
  • Tokyo Metropolitan Institute for Geriatrics and Gerontology
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jul 2026, 15 months.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 15 months is below that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2025
First posted
Mar 18, 2025
StartActual
Apr 24, 2025
Primary completionActual
Jul 31, 2026
CompletionActual
Sep 1, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06881836
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Apr 24, 2025
Primary completion
Jul 31, 2026
Completion
Sep 1, 2026
Last update
Oct 22, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONO-2020

Start the discussion